Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML

PHASE3CompletedINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

October 14, 2014

Primary Completion Date

July 5, 2021

Study Completion Date

August 16, 2021

Conditions
MDS
Interventions
DRUG

Decitabine

"Decitabine (DAC) will be administered at 20 mg/m2 intravenously daily for 5 days every 28 days. Hydroxyurea may be added during the first 3 cycles if WBC counts \> 30 G/L, and mandatory if WBC \> 50 G/L. The daily dose will be adapted to maintain WBC below 15 to 20 G/L.~Treatment will be continued until an event is reached. Events and thus study exit will be acknowledged only after agreement between the investigator and a Trial Committee."

DRUG

HYDROXYUREA

"Hydroxyurea (HY) 1g/d once daily, with dose adjustments (up to 4g/d) to maintain a WBC count between 5 and 10 G/L. Allopurinol, 300mg/d started at the time of inclusion will be administered to all patients.~Treatment will be continued until an event is reached. Events and thus study exit will be acknowledged only after agreement between the investigator and a Trial Committee."

Trial Locations (45)

13009

Institut Paoli-Calmette, Marseille

14033

CHU Côte de Nacre, Caen

26953

CH Valence, Valence

29609

CHU de Brest - Hôpital Morvan, Brest

30029

CHU de Nîmes, Nîmes

31059

IUCT Oncopole - Département d'hématologie, Toulouse

Iuct Oncopole, Toulouse

33604

CHU de Haut-Lévèque, Pessac

34000

Clinique Beausoleil, Montpellier

34295

Hôpital Saint Eloi, Montpellier

35033

CHU Pontchaillou, Rennes

35510

Hôpital privé Sévigné, Cesson-Sévigné

38043

CHU Albert Michallon, Grenoble

44093

Hopital de l'Hotel Dieu, Nantes

45067

CHR d'Orléans, Orléans

51092

CHU de Reims, Reims

54511

CHU Brabois, Vandœuvre-lès-Nancy

59020

Hôpital Saint Vincent de Paul, Lille

60321

CH de Compiègne, Compiègne

63058

CHU Estaing, Clermont-Ferrand

64100

Centre Hospitalier de La Cote Basque, Bayonne

66046

Centre Hospitalier Joffre, Perpignan

67098

Hôpital Hautepierre, Strasbourg

69495

Centre Hospitalier Lyon Sud, Lyon

72000

CH Le Mans, Le Mans

Clinique Victor Hugo, Le Mans

74374

CH Annecy Genevois, Pringy

75475

Hopital St Louis T4, Paris

76038

Centre Henri Bequerel, Rouen

77100

Centre Hospitalier de Meaux, Meaux

80054

Chu Amiens, Amiens

84000

Ch Avignon, Avignon

86021

CHU Poitiers, Poitiers

87046

CHRU de Limoges, Limoges

90015

Hôpital Nord Franche-Comté, Belfort

91106

Centre Hospitalier Sud-Francilien, Corbeil-Essonnes

93009

Hôpital Avicenne, Bobigny

94010

Centre Henri Mondor, Créteil

94805

Institut gustave Roussy, Villejuif

95000

CH René Dubos, Pontoise

95107

CH Victor Dupouy, Argenteuil

97400

CHU La Réunion - Site nord, Saint-Denis

97410

CHU La Réunion-Site Sud, Saint-Pierre

49 000

CHU d'Angers, Angers

06202

Hopital Archet I, Nice

All Listed Sponsors
collaborator

Janssen-Cilag Ltd.

INDUSTRY

lead

Groupe Francophone des Myelodysplasies

OTHER

NCT02214407 - Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML | Biotech Hunter | Biotech Hunter